Work

Phase 1, multicenter, open-label study of HSK46575 in patients with metastatic castration-resistant prostate cancer progressing after next-generation hormonal agents and chemotherapy.

Year: 2026

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2026.44.16_suppl.5047

Authors: Qiang Wei, Ping Feng, Lu Yang, Jie Tang, Haitao Niu, Yu Cao, Xuecheng Yang, Mingxin Zhang, Jun Guo, Xinan Sheng, Shusuan Jiang, Tao Dai, Xinrong Fan, Hongzhong Liu, Yuping Sun, Benkui Zou, Qingbing Wang, Jianming Guo, Jianguo Zhang, Danfeng Xu

Institutions: Sichuan University, West China Hospital of Sichuan University, National Medical Products Administration, State Key Laboratory of Biotherapy, Affiliated Hospital of Qingdao University, Fudan University, Peking University Cancer Hospital, Zhongshan Hospital, Hunan Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Peking Union Medical College Hospital, Shandong First Medical University, Shandong Tumor Hospital, Anyang Tumor Hospital, Henan University of Science and Technology, First Affiliated Hospital of Henan University of Science and Technology, Ruijin Hospital

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7162494677

Cites:

Cited by:

Related to: